APGE 56.31 Apogee Therapeutics, Inc.
| Range: | 14.19-72.29 | Vol Avg: | 408503 | Last Div: | 0 | Changes: | 3.03 |
| Beta: | 2.32 | Cap: | 3.33B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 14 2023 | Empoloyees: | 91 | ||
| CUSIP: | 03770N101 | CIK: | 0001974640 | ISIN: | US03770N1019 | Country: | US |
| CEO: | Dr. Michael Thomas Henderson M.D. | Website: | https://www.apogeetherapeutics.com | ||||
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Stock Details
Stifel Nicolaus
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow